Overview

Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the effect of concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX pre- a delayed TME compared with 6 cycles XELOX post- a Regular Timing TME in patients with high-risk rectal cancer defined by MRI.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Collaborators:

Affiliated Hospital of Hebei University
Beijing Cancer Hospital
Beijing Friendship Hospital
Chinese PLA General Hospital
Fujian Medical University Union Hospital
Hebei Medical University Fourth Hospital
Nanfang Hospital of Southern Medical University
Peking Union Medical College Hospital
Shanghai Zhongshan Hospital
Shengjing Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Xijing Hospital

Treatments:

Capecitabine